What is the role for mycophenolate mofetil in pediatric renal transplantation?

A. M. Neu, M. Benfield

Research output: Contribution to journalArticle

Abstract

Mycophenolate mofetil (MMF) has gained considerable popularity in pediatric renal transplantation. This popularity is largely a result of data from three large trials of MMF in adult cadaveric transplant patients who demonstrated a decreased rate of acute rejection episodes when treated with cyclosporin A (CsA), prednisone, and MMF compared with those receiving CsA, prednisone, and azathioprine (AZA) or placebo. However, the ability of MMF to reduce acute rejection appears to be limited to the first month post- transplant, and its effectiveness with microemulsion CsA or tacrolimus-based regimens has not been proven. In addition, there are currently no data that convincingly demonstrate that this agent improves graft survival, patient survival, graft function or protects against chronic rejection. Finally, there may be an increased risk for severe cytomegalovirus (CMV) disease and lymphoproliferative disorder with central nervous system involvement in patients treated with MMF. These data call into question the role of MMF in current immunosuppressive regimens.

Original languageEnglish (US)
Pages (from-to)83-87
Number of pages5
JournalPediatric transplantation
Volume3
Issue number1
DOIs
StatePublished - Feb 1 1999

    Fingerprint

Keywords

  • Immunosuppression
  • Mycophenolate mofetil
  • Pediatric
  • Renal
  • Transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this